# Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients

> **NCT01702090** · PHASE4 · COMPLETED · sponsor: **Janssen-Cilag Ltd.** · enrollment: 10 (actual)

## Conditions studied

- HIV-1

## Interventions

- **DRUG:** TMC114/ritonavir

## Key facts

- **NCT ID:** NCT01702090
- **Lead sponsor:** Janssen-Cilag Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2016-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01702090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01702090, "Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01702090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*